Adenosine Therapeutics Overview

  • Founded
  • 1999
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $36.2M
Latest Deal Amount

Adenosine Therapeutics General Information


Developer of novel pharmaceutical products that target adenosine receptor subtypes. The company develops drugs for the treatment of asthma, diabetes, Parkinsonís disease, cancer, ophthalmic disease and inflammatory indications such as sepsis, heart attack, ischemia-reperfusion injury, sickle cell crisis, vascular injury, arthritis, spinal cord injury, COPD and inflammatory bowel disease.

Contact Information

Ownership Status
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Primary Office
  • 310 4th Street North East
  • Court Square Building, Second Floor
  • Charlottesville, VA 22905
  • United States
+1 (434) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Adenosine Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 05-Aug-2008 $36.2M 000.00 000.00 Completed Generating Revenue
2. Later Stage VC 01-Nov-2007 00.00 000.00 Completed Generating Revenue
1. Later Stage VC (Series C) 18-Jun-2007 $14M $14M Completed Generating Revenue
To view Adenosine Therapeutics’s complete valuation and funding history, request access »

Adenosine Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Robert Capon Chief Executive Officer & Co-Founder
Joel Linden Ph.D Co-Founder
You’re viewing 2 of 3 executive team members. Get the full list »

Adenosine Therapeutics Former Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ATEL Capital Group Growth/Expansion Minority 000 0000 000000 0
Novartis Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
To view Adenosine Therapeutics’s complete investors history, request access »